How hayfever works: The Full Evidence

What drives Th2 immune dominance?

What the research says

Th2 immune dominance in allergic rhinitis is driven by a coordinated cascade initiated at epithelial barrier disruption, where allergen proteases, lipids, and extracellular vesicles activate innate immune signals that bias dendritic cells toward Th2-polarizing antigen presentation. This triggers naive CD4+ T cell differentiation via IL-4/STAT6/GATA-3 signaling, establishing Th2 lineage commitment and sustained production of IL-4, IL-5, and IL-13, which collectively orchestrate IgE class switching, eosinophil recruitment, and mucus hypersecretion. Reciprocal suppression of Th1 responses through IL-10 and IL-6-mediated IFN-γ inhibition self-reinforces and stabilizes the Th2-dominant state.

How it works

IL-4 activates STAT6, which upregulates the master transcription factor GATA-3, locking CD4+ T cells into Th2 lineage commitment and driving autocrine amplification of the Th2 cytokine program; simultaneously, allergen-derived proteases disrupt epithelial tight junctions and activate protease-activated receptor-2, generating oxidative stress signals and innate alarmins that prime the upstream dendritic cell environment toward Th2 polarization before adaptive responses are engaged.

---

Why do mast cells become hypersensitive?

What the research says

Mast cell hypersensitivity develops primarily through IgE-dependent upregulation of the high-affinity receptor FcεRI, where increasing IgE levels drive 2-5 fold increases in surface FcεRI expression, lowering the allergen threshold for degranulation by approximately 10-fold and amplifying mediator release (e.g., 73% more histamine, 156% more LTC4). Sensitization occurs when allergen crosslinks IgE-FcεRI complexes, triggering rapid release of preformed mediators (histamine, tryptase, TNF-α) and de novo synthesis of lipid mediators and cytokines (IL-4, IL-13, PGD2). Additional amplification arises from non-IgE pathways including innate receptor signaling (TLRs, ST2/IL-33), galectin-3 crosslinking, and neuropeptides such as substance P, collectively sustaining feedforward hypersensitivity loops.

How it works

Upon allergen re-exposure, crosslinking of IgE-occupied FcεRI receptors triggers ITAM-mediated phosphorylation cascades (amplified ~100-fold by the FcεRIβ subunit), rapidly activating downstream signaling (Lyn, Syk, PLCγ) that drives degranulation and cytokine synthesis; the resulting IL-4/IL-13 promote further local IgE production and Th2 skewing, while TNF-α matures dendritic cells, creating a self-reinforcing sensitization cycle.

---

How do IgE levels correlate with symptoms?

What the research says

Allergen-specific IgE (sIgE) demonstrates a meaningful but imperfect correlation with allergic rhinitis symptom severity, with high sIgE levels (>50 kU/L) associated with approximately 2-fold greater symptom burden in untreated patients. In contrast, total serum IgE shows inconsistent and generally unreliable correlation with symptom severity across multiple studies spanning nearly four decades, from Nickeisen et al. (1986) to recent 2024-2025 investigations. The relationship is further complicated by patient age, sensitization pattern, allergen exposure, and disease phenotype (seasonal vs. perennial).

How it works

Allergen-specific IgE sensitizes mast cells and basophils via high-affinity FcεRI receptors; upon allergen re-exposure, crosslinking of bound sIgE triggers degranulation and release of histamine, leukotrienes, and cytokines, directly driving nasal symptoms — explaining why sIgE quantity is more mechanistically linked to symptom intensity than polyclonal total IgE. Total IgE reflects broader atopic burden and non-specific sensitization, diluting its predictive signal for any single allergen-driven symptom response.

---

Which cytokines drive allergic rhinitis symptoms?

What the research says

Strong and consistent evidence from multiple mechanistic reviews and clinical studies identifies IL-4, IL-5, IL-13, IL-33, and TSLP as the primary cytokines driving allergic rhinitis symptoms, operating through a Th2-skewed inflammatory cascade. IL-4 and IL-13 promote IgE production and mucus hypersecretion, IL-5 drives eosinophil recruitment and tissue damage, while epithelial alarmins IL-33 and TSLP amplify the response via dendritic cell conditioning and ILC2 activation. Additional mediators including TNF-α, GM-CSF, and TGF-β contribute to disease severity, with quantitative data showing serum IL-4 levels 2.1–2.8 times higher in AR patients versus controls.

How it works

Allergen exposure cross-links IgE on sensitized mast cells, triggering immediate histamine/leukotriene release and subsequent Th2 cytokine secretion (IL-4, IL-5, IL-13) that sustains late-phase eosinophilic inflammation and goblet cell hyperplasia; concurrently, epithelial barrier damage releases alarmins (IL-33, TSLP) that condition dendritic cells for Th2 priming and activate ILC2s, creating a self-amplifying inflammatory loop responsible for nasal congestion, rhinorrhea, and sneezing.

---

Why do some people outgrow allergies?

What the research says

Some individuals naturally outgrow allergies through the development of allergen-specific immune tolerance, driven primarily by regulatory T cells (Tregs/Tr1 cells) and regulatory B cells (Br1 cells) that actively suppress pathological Th2 responses. The shift toward tolerance is characterized by increased IL-10 production, IgG4 class switching, and the generation of allergen-specific memory B cells — mechanisms documented both in spontaneous tolerance and therapeutically-induced tolerance via immunotherapy. Evidence from cow's milk allergy specifically shows that children who naturally outgrow the allergy exhibit increased frequencies of circulating allergen-specific B cells, paralleling changes seen with oral immunotherapy.

How it works

IL-10-secreting Tr1 regulatory T cells suppress allergic responses by inhibiting CD28/ICOS-dependent T cell costimulation, downregulating MHC class II on antigen-presenting cells, and driving B cells toward IgG4 production rather than IgE; IgG4 acts as a non-inflammatory 'blocking' antibody that competes with IgE at mast cell and basophil receptors, thereby preventing degranulation and allergic symptoms. Regulatory B cells further reinforce this tolerogenic state through antigen-specific suppression.

---

Can immune tolerance be retrained?

What the research says

Yes, immune tolerance can be retrained through allergen-specific immunotherapy (AIT), which is currently the only treatment modality demonstrated to alter the natural course of allergic diseases including allergic rhinitis. Multiple high-quality RCTs and systematic reviews confirm that ≥3 years of AIT (subcutaneous or sublingual) produces durable, disease-modifying tolerance that can persist for years after treatment cessation, with symptom-medication score improvements of approximately 50-70% versus placebo. Shorter courses (e.g., 2 years) yield only transient benefits, underscoring the importance of treatment duration for sustained immunological reprogramming.

How it works

AIT retrains immune tolerance through three converging mechanisms: induction and expansion of allergen-specific regulatory T cells (Tregs, both FOXP3+CD4+CD25+ and IL-10/TGF-β-producing Tr1 cells) that suppress Th2-driven allergic inflammation; a class-switch from pathogenic IgE to blocking IgG4 antibodies (up to 100-fold increase) that competitively inhibit allergen-IgE binding on mast cells and basophils; and progressive desensitization of mast cells and basophils, reducing histamine release and downstream effector responses.

---

What regulates mast cell activation thresholds?

What the research says

Mast cell activation thresholds are regulated by a dynamic balance between activating and inhibitory signaling networks converging on FcεRI. Inhibitory receptors (FcγRIIB, SHIP1) raise thresholds by dampening PI3K/Akt and Ca²⁺ signaling, while co-stimulatory inputs from cytokines (IL-33, SCF, IL-4), GPCRs, and TLR ligands lower thresholds by priming FcεRI expression and downstream Syk/LAT/PLCγ signaling. IgE sensitization levels further modulate thresholds by increasing FcεRI surface density, reducing the antigen concentration required to trigger degranulation by up to 100-fold.

How it works

FcεRI crosslinking initiates Syk-dependent phosphorylation of LAT, activating PLCγ to generate IP₃ and DAG, which mobilize intracellular Ca²⁺ and activate PKC/MAPK cascades required for degranulation; this threshold is raised by SHIP1-mediated PIP₃ hydrolysis downstream of inhibitory FcγRIIB co-ligation, and lowered by PI3K amplification via co-stimulatory receptors and cytokine-induced upregulation of proximal signaling components.

---

Do regulatory T cells reduce allergic symptoms?

What the research says

Regulatory T cells (Tregs) play a significant role in suppressing allergic rhinitis symptoms, with multiple studies demonstrating that AR patients exhibit reduced circulating Treg numbers and impaired Treg function compared to healthy controls. Allergen-specific IL-10-secreting Tr1 cells are notably decreased in persistent AR, and allergen immunotherapy (SIT) works in part by enhancing Treg immunosuppressive activity and increasing circulating Treg populations. The Th17/Treg imbalance is now recognized as a key pathogenic axis in AR, with restoration of this balance representing a therapeutic target.

How it works

Tregs suppress Th2-driven allergic inflammation primarily through secretion of IL-10, TGF-β, and IL-35, which inhibit IgE production, mast cell and eosinophil activation, and effector T/B cell proliferation while promoting immunoglobulin class switching toward IgG4/IgA. Additional suppression occurs via cell-contact-dependent mechanisms including CTLA-4 and CD39/CD73 signaling, and follicular Tregs (Tfr) limit IgE production by inhibiting Tfh-B cell interactions.